236 related articles for article (PubMed ID: 21143970)
1. Ligands specify estrogen receptor alpha nuclear localization and degradation.
Kocanova S; Mazaheri M; Caze-Subra S; Bystricky K
BMC Cell Biol; 2010 Dec; 11():98. PubMed ID: 21143970
[TBL] [Abstract][Full Text] [Related]
2. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
3. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1.
Stenoien DL; Mancini MG; Patel K; Allegretto EA; Smith CL; Mancini MA
Mol Endocrinol; 2000 Apr; 14(4):518-34. PubMed ID: 10770489
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.
Long X; Nephew KP
J Biol Chem; 2006 Apr; 281(14):9607-15. PubMed ID: 16459337
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
8. The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor.
Casa AJ; Hochbaum D; Sreekumar S; Oesterreich S; Lee AV
Mol Cell Endocrinol; 2015 Nov; 415():76-86. PubMed ID: 26272024
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.
Berry NB; Fan M; Nephew KP
Mol Endocrinol; 2008 Jul; 22(7):1535-51. PubMed ID: 18388150
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
13. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
[TBL] [Abstract][Full Text] [Related]
14. Role of SUMOylation in full antiestrogenicity.
Hilmi K; Hussein N; Mendoza-Sanchez R; El-Ezzy M; Ismail H; Durette C; Bail M; Rozendaal MJ; Bouvier M; Thibault P; Gleason JL; Mader S
Mol Cell Biol; 2012 Oct; 32(19):3823-37. PubMed ID: 22826433
[TBL] [Abstract][Full Text] [Related]
15. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
16. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
[TBL] [Abstract][Full Text] [Related]
17. Clomiphene citrate down-regulates estrogen receptor-α through the ubiquitin-proteasome pathway in a human endometrial cancer cell line.
Amita M; Takahashi T; Igarashi H; Nagase S
Mol Cell Endocrinol; 2016 Jun; 428():142-7. PubMed ID: 27033325
[TBL] [Abstract][Full Text] [Related]
18. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
19. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.
Bai Y; Giguére V
Mol Endocrinol; 2003 Apr; 17(4):589-99. PubMed ID: 12554772
[TBL] [Abstract][Full Text] [Related]
20. Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
Giamarchi C; Chailleux C; Calligé M; Rochaix P; Trouche D; Richard-Foy H
Biochim Biophys Acta; 2002 Oct; 1578(1-3):12-20. PubMed ID: 12393183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]